TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
TherapeuticsMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.86−0.04 (-2.11%)
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
TherapeuticsMD statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Market Cap | $21.53M | $166.30M |
| Enterprise Value | $12.34M | $88.19M |
| PS Ratio | 6.58 | 3.65 |
| PB Ratio | 0.79 | 2.03 |
| P/TBV Ratio | 0.91 | 2.29 |
| P/OCF Ratio | 6.95 | 12.98 |
Enterprise value
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| EV / Sales | 3.77 | 2.51 |
Income (trailing twelve months)
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Revenue | $3.27M | $58.34M |
| Operating Income | -$3.95M | -$21.40M |
| Pretax Income | -$263.00K | -$14.34M |
| Net Income | -$217.00K | -$22.46M |
| EBITDA | -$3.57M | -$16.91M |
| EPS (Diluted) | -$0.02 | -$0.83 |
Margins
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Operating Margin | -120.9% | -44.0% |
| Pretax Margin | -8.04% | -13.3% |
| Profit Margin | -6.64% | -40.2% |
| EBITDA Margin | -109.2% | -30.2% |
Returns
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Return on Equity (ROE) | -0.80% | -53.2% |
| Return on Assets (ROA) | -0.57% | -40.9% |
| Return on Invested Capital (ROIC) | -15.9% | -32.4% |
| Return on Capital Employed (ROCE) | -12.2% | -38.1% |
Growth
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 27.8% | 5.96% |
| Revenue Growth (3Y CAGR) | -64.9% | 2.25% |
| Revenue Growth (5Y CAGR) | -45.8% | 6.48% |
Balance sheet
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.19M | $61.43M |
| Net Cash (Debt) | $9.19M | $15.35M |
| Net Cash Per Share | $0.79 | $0.66 |
| Equity (Book Value) | $27.13M | $49.09M |
| Book Value Per Share | $2.34 | $1.37 |
| Tangible Book Value | $23.57M | $23.52M |
| Working Capital | $11.12M | $76.81M |
Financial position
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Current Ratio | 3.22 | 3.34 |
| Quick Ratio | 1.84 | 2.44 |
Cash flow (trailing twelve months)
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Operating Cash Flow | $3.10M | -$12.35M |
Efficiency
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Asset Turnover | 0.09 | 0.39 |
| Revenue Per Employee | $3.27M | $404.87K |
| Profits Per Employee | -$217.00K | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Earnings Yield | -1.01% | -23.3% |
Shares
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Shares Outstanding | 11,574,400 | 58,127,000 |
| Shares Change (YoY) | 0.44% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 11,394,200 | 49,136,700 |
| Shares Held by Insiders | 1.56% | 11.6% |
| Shares Held by Institutions | 31.7% | 59.4% |
Scores
| Measure | TherapeuticsMD | Industry median |
|---|---|---|
| Altman Z-Score | -34.18 | -0.22 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from TherapeuticsMD's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.